Prevalence of Metallo-Beta-Lactamase Among Pseudomonas Aeruginosa and Acinetobacter Baumannii in a Korean University Hospital and Comparison of Screening Methods for Detecting Metallo-Beta-Lactamase

J Microbiol Methods. 2003 Sep;54(3):411-8. doi: 10.1016/s0167-7012(03)00090-3.

Abstract

To identify the metallo-beta-lactamases (MBLs) prevalent in Korea, a total of 130 clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii (99 P. aeruginosa and 31 A. baumannii) with a reduced susceptibility to imipenem (IPM) and/or ceftazidime (CAZ) was subjected to PCR analyses with primers specific to bla(IMP-1), bla(VIM-1), and bla(VIM-2). In addition, inhibitor-potentiated disk diffusion methods (IPD) using two kinds of substrate-inhibitor combinations (ceftazidime-2-mercaptopropionic acid (2MPA) and imipenem-EDTA) were investigated. Thirty-three isolates (29 P. aeruginosa and 4 A. baumannii) carried bla(VIM-2) and two P. aeruginosa isolates harbored bla(IMP-1). The enterobacterial repetitive intergenic consensus PCR (ERIC-PCR) pattern revealed that many of the VIM-2-producing P. aeruginosa isolates were clonally related, whereas the A. baumannii isolates were diverse. The inhibitor-potentiated disk diffusion test using imipenem-EDTA was highly sensitive and specific for detecting the VIM-2 producer. These results suggest that VIM-2 is an important MBL in P. aeruginosa and A. baumannii in the Korean hospital of this study and that the IMP-1-producing P. aeruginosa has also emerged. Screening for MBLs and strict infection control for these isolates will contribute to prevent further spread of resistance.

Publication types

  • Comparative Study

MeSH terms

  • Acinetobacter / enzymology*
  • Acinetobacter / genetics
  • Acinetobacter / growth & development
  • Acinetobacter Infections / drug therapy
  • Acinetobacter Infections / microbiology*
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Ceftazidime / pharmacology
  • Ceftazidime / therapeutic use
  • DNA Fingerprinting
  • DNA, Bacterial / chemistry
  • DNA, Bacterial / genetics
  • Drug Resistance, Bacterial / genetics
  • Humans
  • Imipenem / pharmacology
  • Imipenem / therapeutic use
  • Korea
  • Microbial Sensitivity Tests / methods
  • Polymerase Chain Reaction
  • Pseudomonas Infections / drug therapy
  • Pseudomonas Infections / microbiology*
  • Pseudomonas aeruginosa / enzymology*
  • Pseudomonas aeruginosa / genetics
  • Pseudomonas aeruginosa / growth & development
  • ROC Curve
  • Sulfhydryl Compounds / pharmacology
  • beta-Lactamases / genetics
  • beta-Lactamases / metabolism*

Substances

  • Anti-Bacterial Agents
  • DNA, Bacterial
  • Sulfhydryl Compounds
  • Imipenem
  • Ceftazidime
  • VIM-1 metallo-beta-lactamase
  • beta-lactamase IMP-1
  • beta-Lactamases
  • thiolactic acid